Please enter verification code
Confirm
High Ferritin Before Transplant Increases Cytopenia Post-transplant in HLA Mismatched Hematopoietic Stem Cell Transplantation in β-Thalassemia Major
American Journal of Pediatrics
Volume 4, Issue 2, June 2018, Pages: 31-35
Received: Apr. 13, 2018; Accepted: May 24, 2018; Published: Jun. 14, 2018
Views 2152      Downloads 120
Authors
Liao Jianyun, Department of Pediatrics, Nanfang Hospital, Southern Medical University, Guangzhou, China
Issa Moussa Mardo, Department of Pediatrics, Nanfang Hospital, Southern Medical University, Guangzhou, China
Wen Jianyun, Department of Pediatrics, Nanfang Hospital, Southern Medical University, Guangzhou, China
Zhou Xiaohui, Department of Pediatrics, Nanfang Hospital, Southern Medical University, Guangzhou, China
Peng Zhiyong, Department of Pediatrics, Nanfang Hospital, Southern Medical University, Guangzhou, China
Liu Huaying, Department of Pediatrics, Nanfang Hospital, Southern Medical University, Guangzhou, China
Chen Libai, Department of Pediatrics, Nanfang Hospital, Southern Medical University, Guangzhou, China
He Yuelin, Department of Pediatrics, Nanfang Hospital, Southern Medical University, Guangzhou, China
Pei Fuyu, Department of Pediatrics, Nanfang Hospital, Southern Medical University, Guangzhou, China
Wu Xuedong, Department of Pediatrics, Nanfang Hospital, Southern Medical University, Guangzhou, China
Feng Xiaoqin, Department of Pediatrics, Nanfang Hospital, Southern Medical University, Guangzhou, China
Bai Jing, Department of Pediatrics, Nanfang Hospital, Southern Medical University, Guangzhou, China
Su Qingxia, Department of Pediatrics, Nanfang Hospital, Southern Medical University, Guangzhou, China
Li Chunfu, Department of Pediatrics, Nanfang Hospital, Southern Medical University, Guangzhou, China
Article Tools
Follow on us
Abstract
The objective is to find out the causes of Cytopenia post-engraftment (CPE) in hematopoietic stem cell transplantation (HSCT) for patients with β-thalassemia major (β-TM). For this, 61 consecutive β-TM patients underwent 7/8 HLA matched HSCT from January 1, 2009 to June 30, 2015 were retrospectively analyzed. Thirty-eight patients suffered from CPE and the remainder (n=23) associated without CPE. The effect of pre-transplant ferritin (PTF) and recipient and donor age on CPE were analyzed in the two groups. The CPE was defined as white blood cell counts less than 3.0×109/L for four weeks or longer without infection of cytomegalovirus, human parvovirus B19 virus and Epstein-Barr virus. As result, in univariate analysis, PTF level was a high-risk factor for CPE and significant higher in CPE group than no-CPE group (3927.9 ± 1314.9 vs 2291.0 ± 994.4 ng/ml, p=0.000). The result was also proved by multi-factor binary regression analysis (p=0.001). The optimal value of PTF level by R language (R 2.15.2) is 2500ng/ml, which is cutoff value in the two groups. The current study showed high PTF level was a high-risk factor of CPE for β-TM patients underwent 7/8 HLA-matched HSCT. PTF should be reduced below 2500ng/L if the 7/8 matched HSCT must be done.
Keywords
Ferritin, Cytopenia, Thalassemia, HSCT
To cite this article
Liao Jianyun, Issa Moussa Mardo, Wen Jianyun, Zhou Xiaohui, Peng Zhiyong, Liu Huaying, Chen Libai, He Yuelin, Pei Fuyu, Wu Xuedong, Feng Xiaoqin, Bai Jing, Su Qingxia, Li Chunfu, High Ferritin Before Transplant Increases Cytopenia Post-transplant in HLA Mismatched Hematopoietic Stem Cell Transplantation in β-Thalassemia Major, American Journal of Pediatrics. Vol. 4, No. 2, 2018, pp. 31-35. doi: 10.11648/j.ajp.20180402.13
Copyright
Copyright © 2018 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
References
[1]
Rachmilewitz, E.A. and P.J. Giardina, How I treat thalassemia. Blood, 2011. 118(13): p. 3479-88.
[2]
Elborai, Y., A. Uwumugambi, and L. Lehmann, Hematopoietic stem cell transplantation for thalassemia. Immunotherapy, 2012. 4(9): p. 947-56.
[3]
Modell, B., et al., Improved survival of thalassaemia major in the UK and relation to T2* cardiovascular magnetic resonance. J Cardiovasc Magn Reson, 2008. 10: p. 42.
[4]
Ferrari, G., M. Cavazzana, and F. Mavilio, Gene Therapy Approaches to Hemoglobinopathies. Hematol Oncol Clin North Am, 2017. 31(5): p. 835-852.
[5]
Baronciani, D., et al., Hemopoietic stem cell transplantation in thalassemia: a report from the European Society for Blood and Bone Marrow Transplantation Hemoglobinopathy Registry, 2000-2010. Bone Marrow Transplant, 2016. 51(4): p. 536-41.
[6]
Gaziev, J., et al., Bone marrow transplantation for thalassemia from alternative related donors: improved outcomes with a new approach. Blood, 2013.
[7]
Jaing, T.H., et al., Unrelated cord blood transplantation for thalassaemia: a single-institution experience of 35 patients. Bone Marrow Transplant, 2012. 47(1): p. 33-9.
[8]
Bakhshi, S. and B. Biswas, Cytomegalovirus in hematological malignancies. Indian Pediatr, 2013. 50(2): p. 193-4.
[9]
Hsu, W.Y., et al., Successful management of multilineage autoimmune cytopenia complicated with severe infection and deep vein thrombosis in a patient with Hodgkin lymphoma post-autologous hematopoietic stem cell transplantation. Pediatr Transplant, 2016. 20(1): p. 168-71.
[10]
Waespe, N., U. Zeilhofer, and T. Gungor, Treatment-refractory multi-lineage autoimmune cytopenia after unrelated cord blood transplantation: remission after combined bortezomib and vincristine treatment. Pediatr Blood Cancer, 2014. 61(11): p. 2112-4.
[11]
Teachey, D.T. and M.P. Lambert, Diagnosis and management of autoimmune cytopenias in childhood. Pediatr Clin North Am, 2013. 60(6): p. 1489-511.
[12]
Li, C., et al., A novel conditioning regimen improves outcomes in beta-thalassemia major patients using unrelated donor peripheral blood stem cell transplantation. Blood, 2012. 120(19): p. 3875-81.
[13]
Altes, A., et al., Iron overload might increase transplant-related mortality in haematopoietic stem cell transplantation. Bone Marrow Transplant, 2002. 29(12): p. 987-9.
[14]
Holbro, A., M. Abinun, and T. Daikeler, Management of autoimmune diseases after haematopoietic stem cell transplantation. Br J Haematol, 2012. 157(3): p. 281-90.
[15]
Bhatt, V., et al., Autoimmune hemolysis and immune thrombocytopenic purpura after cord blood transplantation may be life-threatening and warrants early therapy with rituximab. Bone Marrow Transplant, 2016. 51(12): p. 1579-1583.
[16]
Thambiah, S.C., et al., Pre-transplantation serum ferritin as a prognostic marker in allogeneic haemopoietic stem cell transplant patients in a tertiary care hospital in Malaysia. Natl Med J India, 2016. 29(0970-258X (Print)): p. 136-140.
[17]
Shaw, B.E., et al., The impact of HLA genotyping on survival following unrelated donor haematopoietic stem cell transplantation. Br J Haemato, 2010. 150(1365-2141 (Electronic)): p. 251-8.
[18]
Oran, B., et al., Better allele-level matching improves transplant-related mortality after double cord blood transplantation. Haematologica, 2015. 100(10)(1592-8721 (Electronic)): p. 1361-70.
[19]
de Witte, T., The role of iron in patients after bone marrow transplantation. Blood Rev, 2008. 22(1532-1681 (Electronic)): p. 22-8.
[20]
Sucak, G.T., et al., Iron overload: predictor of adverse outcome in hematopoietic stem cell transplantation. Transplant Proc, 2010. 42 (5) (1873-2623 (Electronic)): p. 1841-8.
[21]
Kataoka, K., et al., Influence of pretransplantation serum ferritin on nonrelapse mortality after myeloablative and nonmyeloablative allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant, 2009. 15(2)(1523-6536 (Electronic)): p. 195-204.
[22]
Majhail, N.S., L.J. Lazarus Hm Fau - Burns, and L.J. Burns, Iron overload in hematopoietic cell transplantation. Bone Marrow Transplant, 2008 41(0268-3369 (Print)): p. 997-1003.
[23]
Pullarkat, V., et al., Iron overload adversely affects outcome of allogeneic hematopoietic cell transplantation. Bone Marrow Transplant, 2008. 42(12)(1476-5365 (Electronic)): p. 799-805.
[24]
Mahindra, A., et al., Elevated ferritin is associated with relapse after autologous hematopoietic stem cell transplantation for lymphoma. Biol Blood Marrow Transplant, 2008 14(1523-6536 (Electronic)): p. 1239-44.
[25]
Recalcati, S., et al., New functions for an iron storage protein: the role of ferritin in immunity and autoimmunity. J Autoimmun, 2008. 30(0896-8411 (Print)): p. 84-9.
[26]
Gray, C.P., P. Arosio P Fau - Hersey, and P. Hersey, Heavy chain ferritin activates regulatory T cells by induction of changes in dendritic cells. Blood, 2002. 99(9)(0006-4971 (Print)): p. 3326-34.
[27]
Sakamoto, S., et al., Differing impacts of pretransplant serum ferritin and C-reactive protein levels on the incidence of chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Int J Hematol, 2013. 97(1865-3774 (Electronic)): p. 109-16.
ADDRESS
Science Publishing Group
1 Rockefeller Plaza,
10th and 11th Floors,
New York, NY 10020
U.S.A.
Tel: (001)347-983-5186